What Ультрапрокт Treats: Main Uses and Benefits

Ультрапрокт is generally intended for supportive symptomatic relief in certain anal and rectal conditions. It is applied across domains where additional symptomatic support is needed to address discomfort and tension. This includes conditions such as acute flare-ups of hemorrhoids (piles), proctitis (inflammation of the rectal lining), and anal fissures.

This medication is used to address symptoms related to inflammatory or irritative states, which encompasses local pain, intense burning, general soreness, and swelling. It is helpful in situations where multiple symptoms occur together, and offers symptomatic relief that helps ease the overall symptom burden. The medication is relevant in clinical settings marked by heightened patient distress, supporting patients during difficult episodes by easing distress. This assists with managing symptoms that interfere with routine activities and contributes to improved day-to-day comfort.

---

Quick Fact: Relief for Inflammation, Pain, and Itching

Regulatory References

1. Summary of Product Characteristics approved by the Health Products Regulatory Authority (HPRA)

Who Can and Cannot Use Ultraproct: Official Regulatory Information

The eligibility for using Ultraproct (Ультрапрокт) is strictly defined by regulatory documents based on contraindications and patient restrictions. Use is generally established for adults seeking symptomatic relief for conditions like hemorrhoids and proctitis.

---

Absolute Prohibitions (Contraindications)

Classification	Restriction
Hypersensitivity	Patients with known allergy to the active substances (Fluocortolone esters, Cinchocaine) or any excipients.
Local Pathology	Presence of local viral diseases (e.g., herpes, shingles), tuberculous, or syphilitic processes in the treatment area.
Infections	Untreated primary bacterial or fungal infections in the area of application.

---

Population Restrictions and Conditional Use

Classification	Restriction
Infants	Not for use.
Children under 12	Not recommended unless directed by a physician.
First Trimester	Should not be applied during the first three months of pregnancy.
Pregnancy/Lactation	Prolonged use must be avoided; the clinical indication must be carefully reviewed.
Conditional Use	Patients with bacterial or fungal infections must receive additional specific anti-infective therapy.

Regulatory agencies classify the presence of a local viral infection or hypersensitivity as an absolute contraindication, meaning the medicine must not be used under these circumstances.

Interactions with other medicines and products

The official regulatory documentation for Ультрапрокт details specific restrictions concerning metabolic drug interactions and excipient-mediated product effects.

Drug–Drug Metabolic Interactions

The most significant restriction relates to medicinal products classified as CYP3A inhibitors. This enzyme system is responsible for the clearance of the corticosteroid component, Fluocortolone. Co-treatment with CYP3A inhibitors is expected to result in a pharmacokinetic interaction, which increases the risk of systemic side-effects from the corticosteroid.

Official prescribing information states that co-treatment with these inhibitors, including specific agents such as cobicistat-containing products, should be avoided. If this combination is deemed necessary, regulatory documents require that the patient be monitored for signs of systemic corticosteroid effects.

Excipient and Product Interactions

The excipients within the ointment and suppository formulations can interact with certain products applied to the same area. Specifically, components such as castor oil may compromise the structural integrity and thus reduce the effectiveness of latex products, such as condoms, used concurrently. No other specific interactions with food, alcohol, or herbal products are formally documented in the official regulatory information.

How Ультрапрокт Works

Ультрапрокт acts via a dual pharmacodynamic mechanism involving its two active components. The corticosteroid, fluocortolone, enters target cells and binds to the intracellular glucocorticoid receptor (GR). This complex translocates to the nucleus where it acts as a transcription factor, specifically repressing the genetic expression of the enzyme Phospholipase A2 ( PLA2). Reduced PLA2 activity subsequently limits the release of arachidonic acid, thereby constraining the synthesis of inflammatory mediators like prostaglandins and leukotrienes.

Concurrently, the local anesthetic, cinchocaine, interacts with voltage-gated sodium channels embedded in nerve cell membranes. This interaction prevents the rapid influx of sodium ions necessary for channel activation and disrupts the depolarization phase of the action potential. This localized blockade prevents the initiation and propagation of sensory nerve signals, modulating nociceptive input at the tissue level.

The medicine is available as an ointment for topical or rectal use and as suppositories for rectal administration. The standard protocol for administration requires the anal region to be cleaned thoroughly and the product to be applied after defaecation.

Dosing Regimens and Frequency

Usage Phase	Ointment Application	Suppository Insertion
Initial (Acute Symptoms)	Up to four times daily on the first day.	Up to two or three times daily on the first day.
Standard/Maintenance	Generally twice daily.	Generally once daily.

For internal rectal application, the ointment requires the use of the enclosed nozzle, and suppositories should be inserted high into the rectum. A standard ointment dose is generally measured as an amount approximating the size of a pea. If suppositories soften due to heat, they must be immersed in cold water prior to opening and handling.

---

Duration and Step-Down

The duration of treatment should generally not exceed four weeks. To maintain the therapeutic effect and reduce the potential for symptom relapse, a reduced frequency regimen must be continued for at least one week after symptoms have fully resolved. This reduced pattern typically involves using the ointment once daily or inserting a suppository every other day. Regarding specific populations, the product is not for use in infants and is not generally recommended for children under 12 years of age unless expressly directed.

Research evidence / Overview of studies for Ультрапрокт

---

Evidence Structure for Acute Hemorrhoids

Research examining the combination product containing Fluocortolone and Cinchocaine has been conducted in adult populations experiencing acute hemorrhoidal flare-ups. The studies used in research exploring how symptoms change over time include non-interventional observational studies and prospective controlled studies. These studies monitored patient-reported outcomes describing perceived discomfort.

Studies conducted during periods of increased symptom activity reported how symptoms evolved in the observed populations over a limited time, generally up to two weeks. Findings described patterns observed in the studies related to reported measurements of change in acute local discomfort, such as pain, itching, and a burning sensation. Research also reported measurements of objective signs like localized swelling (edema) and bleeding.

However, the volume of controlled data remains low to moderate. Evidence is limited by the fact that many of the existing clinical studies utilized older or non-interventional designs. Comparative evidence is lacking for large-scale, modern, blinded studies directly evaluating this specific drug combination against an inactive placebo.

---

Evidence for Proctitis and Anal Fissures and Study Gaps

Research also explored conditions involving periods of heightened symptoms, specifically proctitis (rectal inflammation) and anal fissures. The basis for these indications includes reference to the established anti-inflammatory and anesthetic properties of its components, as well as its inclusion in regulatory scope, rather than a wide body of dedicated clinical trials.

For these conditions, studies examined outcomes linked to inflammatory or irritative states. Findings described measurements related to local comfort and the evolution of inflammatory symptoms over defined time intervals. Data for proctitis and anal fissures remain insufficient, with a lack of prominent, primary research trials focused solely on either condition using this specific combination.

Overall, the research highlights what is known—and what is still uncertain. Follow-up durations were limited to the acute phase, and long-term outcomes are not fully established regarding how the observed short-term patterns endure after treatment is stopped.

Key Studies & References Summary of Product Characteristics approved by the Health Products Regulatory Authority (HPRA) for Ultraproct

Common questions about Ультрапрокт (FAQ)

Q: How quickly can a person generally expect to feel relief after using Ультрапрокт?

Official product information indicates that the cinchocaine component, which is a local anesthetic, is described as providing quick relief from painful and itchy symptoms. This rapid action is stated as part of the overall therapeutic effect when the anesthetic works in combination with the anti-inflammatory steroids.

Q: How does the ointment version of Ультрапрокт differ from the suppository version?

The ointment and suppository forms are described as having differences in their composition, particularly in the concentration of the active ingredients and the excipients (inactive ingredients). Specifically, the ointment contains a higher concentration of Cinchocaine Hydrochloride than the suppository. They are also intended for different uses: the ointment for external and internal use, and the suppository only for internal rectal administration.

Q: Is Ультрапрокт considered a local anesthetic or an anti-inflammatory medicine?

Regulatory documents classify Ультрапрокт as a fixed-dose combination product. It contains two types of active ingredients: a glucocorticoid, which provides the anti-inflammatory effect, and a local anesthetic, which helps numb the painful area. Therefore, it is considered both an anti-inflammatory and an analgesic (pain-relieving) agent.

Q: What should be done if a user accidentally swallows a small amount of the Ультрапрокт ointment or a suppository?

Official regulatory information warns that accidental oral intake of the preparation could lead to systemic effects from the local anesthetic component. These effects are mainly expected to involve the cardiovascular system and, in severe cases, may potentially cause convulsions.

Q: Is the sensation of a mild burn or sting a normal initial experience with Ультрапрокт?

The official safety information notes that local symptoms such as burning, stinging, or tingling may be experienced at the site of application. These sensations are listed among the potential local reactions that can occur when using the product.

Q: How do doctors generally advise patients to clean the area before applying Ультрапрокт?

Official documents state the anal region should be cleaned thoroughly before application. Furthermore, the medicine is best applied after a bowel movement (defaecation) to maximize the contact time.

Q: Can one use a protective dressing over the application area after using Ультрапрокт?

Regulatory documents specifically mention that using this type of medicine with occlusion (covering the area with a dressing) on the perineum, especially in infants, is not appropriate, as this can increase systemic absorption of the corticosteroid component.

Q: Is it normal for the symptoms to return shortly after stopping treatment with Ультрапрокт?

To maintain the full effect of the medicine and to help reduce the potential for symptoms to return (relapse) after they have resolved, official documents advise a reduced frequency regimen. This reduced use is recommended to be continued for at least one week after symptoms have fully disappeared.

Q: What are the specific side effects related to the anesthetic ingredient in Ультрапрокт?

While side effects are generally listed for the combination product, the regulatory information highlights the potential systemic effects of the local anesthetic (cinchocaine hydrochloride) in case of accidental oral intake. These risks include severe cardiovascular depression and convulsions.

Q: Does using Ультрапрокт affect one's ability to drive or operate machinery?

Official regulatory documents state that no effects on the ability to drive or operate machines are known in relation to the use of this medicine.

Q: Can Ультрапрокт be used alongside stool softeners or fiber supplements?

Regulatory documents state that no specific interaction studies have been performed regarding the use of this medicine alongside general products like stool softeners or fiber supplements. Interaction data is limited to co-treatment with certain enzyme inhibitors and the excipient interactions with latex products.

Q: Is it necessary to store the Ультрапрокт ointment and suppositories in the refrigerator?

Storage requirements differ between the two forms. Suppositories must be stored in a refrigerator, at a temperature between 2 C and 8 C. The ointment, however, requires storage only below 25 C.

Q: What are the possible risks if Ультрапрокт gets into the eyes?

Regulatory documents explicitly advise that Ультрапрокт should not be allowed to come into contact with the eyes. Regulatory documents also state that hands should be washed carefully after use.

Q: Can Ультрапрокт be used by adolescents, or is it only approved for adults?

Use of Ультрапрокт is generally established for adults. Regulatory information states that the product is not for use in infants and is not generally recommended for children under 12 years of age, unless specifically directed by a healthcare professional.

Q: Are there different strengths of Ультрапрокт available, and how do they compare?

Official regulatory documents detail only one standard strength for both the ointment form and the suppository form of the medicine. The single strength is composed of a fixed concentration of the two fluocortolone esters and the cinchocaine hydrochloride.

Q: What is the general advice on what to do if a dose of Ультрапрокт is missed?

Regulatory documents describe the general advice that if a dose is missed, it is usually recommended to apply it as soon as it is remembered. If it is almost time for the next dose, the missed dose is typically skipped, and the user continues with the regular schedule.

How to Store and Dispose of Ultraproct

Storage and disposal must strictly follow official regulatory requirements to ensure product stability and safety. The specific temperature requirement is dependent on the dosage form:

• Ointment: Must be stored below 25 C and should be used within 3 months after first opening the tube. The cap must be replaced tightly after use.
• Suppositories: Require storage in a refrigerator (between 2 C and 8 C) and must not be frozen.

All forms must be kept out of the sight and reach of children and retained in their original package.

Expired or unused medication must not be thrown away via wastewater or household waste. Consult a pharmacist for instructions on official pharmaceutical take-back or disposal programs.